series-c-plus
Stage
2
Investors
About
Keros Therapeutics is a clinical-stage biopharmaceutical company that discovers and develops therapies that modulate transforming growth factor‑beta (TGF‑β) family signaling to treat hematological, musculoskeletal, pulmonary, and cardiovascular disorders.
Explore Keros Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.